Novo Holdings backs animal health company Invetx
Novo Holdings today announces it has participated in a $60.5 million oversubscribed Series B financing in Boston-based Invetx, a pioneer in protein-based therapeutics for companion animal health.
The financing allows the Company to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats.
